Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.

Mantia CM, McDermott DF.

Cancer. 2019 Sep 18. doi: 10.1002/cncr.32361. [Epub ahead of print] Review.

PMID:
31532565
2.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.

J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345. [Epub ahead of print]

PMID:
31498030
3.

Sexual activity and cognitive decline in older age: a prospective cohort study.

Smith L, Grabovac I, Yang L, López-Sánchez GF, Firth J, Pizzol D, McDermott D, Veronese N, Jackson SE.

Aging Clin Exp Res. 2019 Sep 7. doi: 10.1007/s40520-019-01334-z. [Epub ahead of print]

PMID:
31494914
4.

Abnormal Newborn Screen in a WHIM Syndrome Infant.

Evans MO 2nd, McDermott DH, Murphy PM, Petersen MM.

J Clin Immunol. 2019 Sep 6. doi: 10.1007/s10875-019-00686-5. [Epub ahead of print] No abstract available.

PMID:
31493092
5.

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.

Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS.

Clin Cancer Res. 2019 Aug 30. doi: 10.1158/1078-0432.CCR-19-0818. [Epub ahead of print]

PMID:
31471309
6.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30413-9. doi: 10.1016/S1470-2045(19)30413-9. [Epub ahead of print] Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
7.

Association between cannabis use and sexual behavior among adolescents aged 12-15 years in 21 low- and middle-income countries.

Smith L, Jackson SE, Jacob L, Grabovac I, Nisbet LA, López-Sánchez GF, McDermott D, Salmeron AG, Yang L, Koyanagi A.

Addict Behav. 2019 Aug 1;99:106073. doi: 10.1016/j.addbeh.2019.106073. [Epub ahead of print]

PMID:
31421584
8.

Human Immunodeficiency Virus Infection and Diverse Physical Health Outcomes: An Umbrella Review of Meta-analyses of Observational Studies.

Grabovac I, Veronese N, Stefanac S, Haider S, Jackson SE, Koyanagi A, Meilinger M, Stubbs B, Firth J, Soysal P, Di Gennaro F, Demurtas J, McDermott DT, Abbs AD, Yang L, Smith L.

Clin Infect Dis. 2019 Aug 11. pii: ciz539. doi: 10.1093/cid/ciz539. [Epub ahead of print]

PMID:
31401650
9.

Syndemic effects of HIV risk behaviours: results from the NHANES study.

Smith L, Cao C, Zong X, McDermott DT, Stefanac S, Haider S, Jackson SE, Veronese N, López-Sánchez GF, Koyanagi A, Yang L, Grabovac I.

Epidemiol Infect. 2019 Jan;147:e241. doi: 10.1017/S095026881900133X.

10.

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.

Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly JD, Sarkar I, Ballinger M, Fassò M, O'Hear C, Chen DS, Hegde PS, Hodi FS.

Clin Cancer Res. 2019 Jul 29. doi: 10.1158/1078-0432.CCR-18-3488. [Epub ahead of print]

PMID:
31358540
11.

Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient.

McDermott DH, Heusinkveld LE, Zein WM, Sen HN, Marquesen MM, Parta M, Rosenzweig SD, Fahle GA, Keller MD, Wiley HE, Murphy PM.

Version 2. F1000Res. 2019 Jan 2 [revised 2019 Jan 1];8:2. doi: 10.12688/f1000research.16825.2. eCollection 2019.

12.

Leisure-Time Sedentary Behavior, Alcohol Consumption, and Sexual Intercourse Among Adolescents Aged 12-15 Years in 19 Countries From Africa, the Americas, and Asia.

Smith L, Jackson SE, Jacob L, Grabovac I, Yang L, Johnstone J, McDermott D, Gordon D, Lopez Sanchez GF, Stefanac S, Koyanagi A.

J Sex Med. 2019 Sep;16(9):1355-1363. doi: 10.1016/j.jsxm.2019.06.013. Epub 2019 Jul 24.

PMID:
31351852
13.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M.

JAMA Oncol. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2187. [Epub ahead of print]

14.

To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.

Pantuck M, McDermott D, Drakaki A.

Cancer. 2019 Jul 18. doi: 10.1002/cncr.32326. [Epub ahead of print] Review.

PMID:
31318445
15.

WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM.

J Clin Immunol. 2019 Aug;39(6):532-556. doi: 10.1007/s10875-019-00665-w. Epub 2019 Jul 16.

PMID:
31313072
16.

Optimizing a Noninvasive Oral Sampling Technique for Semicaptive Neotropical Primates in Peru.

McDermott D, Mendoza AP, Smiley-Evans T, Zavaleta M, Da'Dara AA, Alarcón JO, Bello R, Rosenbaum M.

J Wildl Dis. 2019 Jul 12. [Epub ahead of print]

PMID:
31298968
17.

Improving prescribing for Indigenous Australians.

Moulds RF, McDermott DR.

Med J Aust. 2019 Aug;211(3):111-112. doi: 10.5694/mja2.50269. Epub 2019 Jul 8. No abstract available.

PMID:
31282589
18.

"Big Sister" Wisdom: How might non-Indigenous speech-language pathologists genuinely, and effectively, engage with Indigenous Australia?

McDermott D.

Int J Speech Lang Pathol. 2019 Jun;21(3):252-262. doi: 10.1080/17549507.2019.1617896. Epub 2019 Jun 10.

PMID:
31181968
19.

Holt-Oram Syndrome.

McDermott DA, Fong JC, Basson CT.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2004 Jul 20 [updated 2019 May 23].

20.

Dynamic phases, stratification, laning, and pattern formation for driven bidisperse disk systems in the presence of quenched disorder.

McDermott D, Yang Y, Reichhardt CJO, Reichhardt C.

Phys Rev E. 2019 Apr;99(4-1):042601. doi: 10.1103/PhysRevE.99.042601.

PMID:
31108701
21.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
22.

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Gao X, McDermott DF, Michaelson MD.

Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29. No abstract available.

23.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

McDermott DH, Murphy PM.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646. No abstract available.

PMID:
30995388
24.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
25.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF.

J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.

26.

Ambivalent Homoprejudice towards Gay Men: Theory Development and Validation.

Brooks AS, Luyt R, Zawisza M, McDermott DT.

J Homosex. 2019 Mar 18:1-29. doi: 10.1080/00918369.2019.1585729. [Epub ahead of print]

PMID:
30880630
27.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

28.

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.

Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.

29.

Well-Being Among Older Gay and Bisexual Men and Women in England: A Cross-sectional Population Study.

Grabovac I, Smith L, McDermott DT, Stefanac S, Yang L, Veronese N, Jackson SE.

J Am Med Dir Assoc. 2019 Sep;20(9):1080-1085.e1. doi: 10.1016/j.jamda.2019.01.119. Epub 2019 Mar 1.

PMID:
30827893
30.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

31.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
32.

Tumor Cavity Recurrence after Stereotactic Radiosurgery of Surgically Resected Brain Metastases: Implication of Deviations from Contouring Guidelines.

McDermott DM, Hack JD, Cifarelli CP, Vargo JA.

Stereotact Funct Neurosurg. 2019;97(1):24-30. doi: 10.1159/000496156. Epub 2019 Feb 14.

PMID:
30763944
33.

Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.

Duff K, McDermott D, Luong D, Randolph C, Boxer AL.

J Clin Exp Neuropsychol. 2019 Jul;41(5):469-475. doi: 10.1080/13803395.2019.1572073. Epub 2019 Feb 4.

PMID:
30712468
34.

Power, Process and Context in Theory Based Evaluation of Policy Implementation: A Response to Recent Commentaries.

Lawless A, Baum F, Delany T, MacDougall C, Williams C, McDermott D, van Eyk H.

Int J Health Policy Manag. 2019 Jan 1;8(1):61-62. doi: 10.15171/ijhpm.2018.109. No abstract available.

35.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
36.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

37.

WHIM syndrome: Immunopathogenesis, treatment and cure strategies.

McDermott DH, Murphy PM.

Immunol Rev. 2019 Jan;287(1):91-102. doi: 10.1111/imr.12719. Review.

PMID:
30565238
38.

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.

Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.

Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.

39.

Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB.

mSphere. 2018 Dec 12;3(6). pii: e00645-18. doi: 10.1128/mSphereDirect.00645-18.

40.

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.

McDermott DF, Carducci M.

J Clin Oncol. 2018 Oct 29:JCO1801198. doi: 10.1200/JCO.18.01198. [Epub ahead of print] No abstract available.

PMID:
30372393
41.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

42.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

PMID:
30303516
43.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
44.

Qualitative protocol for understanding the contribution of Australian policy in the urban planning, justice, energy and environment sectors to promoting health and health equity.

Baum F, Delany-Crowe T, Fisher M, MacDougall C, Harris P, McDermott D, Marinova D.

BMJ Open. 2018 Oct 4;8(9):e025358. doi: 10.1136/bmjopen-2018-025358.

45.

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

Hamieh L, Choueiri TK, Ogórek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ.

PLoS Genet. 2018 Sep 26;14(9):e1007679. doi: 10.1371/journal.pgen.1007679. eCollection 2018 Sep.

46.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
47.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators.

Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4.

PMID:
30201421
48.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.

PMID:
30191365
49.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6.

PMID:
30190302
50.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.

Supplemental Content

Loading ...
Support Center